This article is more than 5 years old. Information may no longer be current.

Stryker Spine announces launch of next-generation viable bone matrix at AAOS meeting

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LAS VEGAS - Stryker Corporation's Spine and Trauma and Extremities Divisions recently announced it will launch BIO⁴, a new viable bone matrix, during the American Academy of Orthopaedic Surgeons Annual Meeting here.

Developed by Osiris Therapeutics, BIO⁴ contains endogenous bone-forming cells including mesenchymal stem cells, osteoprogenitor cells, osteoblasts, osteoinductive and angiogenic growth factors. It is a safe alternative to bone autograft that minimizes the potential for harvest-site comorbidities, according to a company press release.

The new product possesses the four characteristics - osteoconductive, osteoinductive, osteogenic and angiogenic - that are important for bone regeneration in a wide range of procedures, the release stated.

Reference: www.stryker.com.